Kadmon Holdings Inc (NYSE:KDMN) has been given an average rating of “Buy” by the seven ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.95.
KDMN has been the topic of several research analyst reports. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Wednesday. Oppenheimer initiated coverage on Kadmon in a research note on Wednesday, June 26th. They set an “outperform” rating and a $6.00 price objective on the stock. ValuEngine downgraded Kadmon from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Cantor Fitzgerald initiated coverage on Kadmon in a research note on Thursday, September 5th. They set an “overweight” rating and a $8.00 price objective on the stock.
A number of institutional investors have recently modified their holdings of KDMN. BNP Paribas Arbitrage SA acquired a new stake in shares of Kadmon in the 1st quarter valued at about $55,000. SG Americas Securities LLC acquired a new stake in shares of Kadmon in the 1st quarter valued at about $55,000. Sawtooth Solutions LLC raised its stake in shares of Kadmon by 3.7% in the 1st quarter. Sawtooth Solutions LLC now owns 342,217 shares of the company’s stock valued at $903,000 after purchasing an additional 12,357 shares during the period. Vivo Capital LLC raised its stake in shares of Kadmon by 20.6% in the 1st quarter. Vivo Capital LLC now owns 12,606,605 shares of the company’s stock valued at $33,281,000 after purchasing an additional 2,152,060 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Kadmon by 343.1% in the 1st quarter. Marshall Wace LLP now owns 147,362 shares of the company’s stock valued at $389,000 after purchasing an additional 114,108 shares during the period. 77.01% of the stock is currently owned by institutional investors and hedge funds.
Shares of KDMN stock traded up $0.08 during trading hours on Friday, reaching $2.67. The company had a trading volume of 23,600 shares, compared to its average volume of 784,817. The company has a 50 day moving average of $2.53 and a 200 day moving average of $2.37. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.99 and a quick ratio of 2.98. The firm has a market cap of $334.46 million, a price-to-earnings ratio of -2.58 and a beta of 2.19. Kadmon has a 1-year low of $1.63 and a 1-year high of $3.21.
Kadmon (NYSE:KDMN) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.03). The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.46 million. Kadmon had a negative net margin of 3,974.23% and a negative return on equity of 96.96%. As a group, sell-side analysts forecast that Kadmon will post -0.54 EPS for the current fiscal year.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Further Reading: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.